Status:
COMPLETED
Effects of rTMS on Cognitive Functions and Behavior in Individuals With Autism Spectrum Disorder
Lead Sponsor:
King Saud University
Conditions:
Autism Spectrum Disorder
Eligibility:
All Genders
5-11 years
Phase:
NA
Brief Summary
Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder with core symptoms that include impairments in social communication and restricted and repetitive behaviors, interests, and acti...
Detailed Description
Statement of the Problem: Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder. Core ASD symptoms include impairments in social communication and restricted and repetitive behavior...
Eligibility Criteria
Inclusion
- Target population:
- Autistic individuals
- previously Diagnosed with ASD using the American Psychiatric Association's DSM-V criteria
- previously Diagnosed using the Autism Diagnostic Observation Schedule (ADOS).
- Male and female ASD individuals
- age between 5 and 11 years old
- diagnosed with ASD on prior clinical assessment using the American Psychiatric Association's DSM-V criteria and corroborated by assessment using the Autism Diagnostic Observation Schedule (ADOS).
- Normal hearing ability based on past hearing screens.
- Participation will be limited to higher functioning (intelligence quotient \[IQ\] \>70) to maximize successful completion of tested paradigms, maintain alertness/attention, furthermore, the ability to follow instructions.
Exclusion
- Individuals that are known to have epilepsy ( including Hx. of febrile convulsion) or have a family history of epilepsy.
- Any individual with a previous Hx. Of head injuries
- Any individual has been diagnosed with psychiatric illness, including ADHD, depression, psychosis, bipolar disorder, anxiety disorders, or OCD.
- Individuals using a combination of Psychotropic Medications known for their significant seizure threshold lowering potential, for example, and not as a limitation: Bupropion, Citalopram, Duloxetine, Fluoxetine, Fluvoxamine, Mirtazapine, Paroxetine, Sertraline, Venlafaxine, Tricyclics, Olanzapine, Quetiapine, Aripiprazole, Ziprasidone, and Risperidone.
- The presence of metallic objects, e.g., cranium clips or implanted biomedical devices.
Key Trial Info
Start Date :
July 20 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2025
Estimated Enrollment :
35 Patients enrolled
Trial Details
Trial ID
NCT06524310
Start Date
July 20 2024
End Date
September 30 2025
Last Update
October 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Physiology, Autism Research and Treatment Center (ARTC), King Saud University Medical City (KSUMC)/Collage of Medicine, King Saud University
Riyadh, Riyadh Region, Saudi Arabia, 12372